替吉奥胶囊联合奈达铂及紫杉醇治疗远处转移鼻咽癌疗效观察

 目的评价替吉奥胶囊(compound tegafur capsule, S-1)联合奈达铂(NDP)及紫杉醇(PTX)方案治疗晚期鼻咽 癌的临床疗效及不良反应。方法治疗晚期远处转移鼻咽癌患者21例，给予S-1 80 mg/m2,分2次，餐后口服，d1~14; NDP 80 mg/m2及PTX 135 mg/m2静脉滴注，第1天；每4周为1周期，所有患者均治疗2~4周期，按RECIST 1. 1标准评 价客观疗效和不良反应。结果CR 3例(14.3%), PR 12例(57.1%), SD 5例(23.8%), PD 1例(4.8%)，RR 71.4%。该方 案最主要的不良反应为骨髓抑制,Ⅲ~Ⅳ度粒细胞减少占71.5%;Ⅱ~Ⅲ度血小板下降占52.3%,其余不良反应则可以耐 受。结论替吉奥联合奈达铂、紫杉醇治疗晚期远处转移鼻咽癌的近期临床疗效较好,不良反应可以耐受,值得临床进 一步研究验证。

Clinical Efficacy of Compound Tegafur Capsule Plus Nedaplatin and Paclitaxel in Treatment of Patients with Distant Metastatic Nasopharyngeal Carcinoma

Objective To evaluate the efficacy and toxicity Compound tegafur capsule(S-1) plus Nedaplatin and Paclitaxel(SNP) regimen in the treatment of distant metastatic nasopharyngeal carcinoma.Methods Twenty-one patients with distant metastatic nasopharyngeal carcinoma were enrolled and treated with S-1 capsule 80 mg/m2 twice daily for 14 days plus nedaplatin 80 mg/m2 and paclitaxel 135 mg/m2 by intravenous drip on d1.Treatment was administered every 3 weeks for 2~4 cycles.Results The total effective rate was 71.4...